Controlled release scaffolds for bone tissue engineering

Journal of Pharmaceutical Sciences

Volumn 98, Issue 2, 2009, Pages 430-441

  Cartmell, Sarah ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Biodegradable polymers; Bone tissue engineering; Controlled release; Delivery vehicle; Growth factor; Microencapsulation; Polymeric drug carrier; Polymeric drug delivery systems; Protein delivery; Scaffold

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALCIUM PHOSPHATE; CHITOSAN; CIPROFLOXACIN; FIBROBLAST GROWTH FACTOR; FLUORIDE SODIUM; GROWTH FACTOR; HYDROXYAPATITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROGOL; NERVE GROWTH FACTOR BETA SUBUNIT; NEUCOLL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; POLYGLACTIN; POLYGLYCOLIDE; POLYLACTIC ACID; POLYLACTIDE; RECOMBINANT VASCULOTROPIN; TOBRAMYCIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BONE DENSITY CONSERVATION AGENT; DRUG CARRIER; SIGNAL PEPTIDE; TISSUE SCAFFOLD;

BONE DEVELOPMENT; BONE MATRIX; BONE MINERAL; BONE TISSUE; CONTROLLED RELEASE FORMULATION; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; HYDROGEL; MICROENCAPSULATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOMYELITIS; OSTEOPOROSIS; REVIEW; TISSUE ENGINEERING; ANIMAL; ARTICLE; BONE; BONE PROSTHESIS; BONE REMODELING; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; DRUG FORMULATION; PATHOPHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE SUBSTITUTES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOGENESIS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 59849087117     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21431     Document Type: Article

References (87)

1. Habraken WJ, Wolke JG, Jansen JA. 2007. Ceramic composites as matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev 59:234-248.
2. Holland TA, Mikos AG. 2006. Biodegradable polymeric scaffolds. Improvements in bone tissue engineering through controlled drug delivery. Adv Biochem Eng Biotechnol 102:161-185.
3. Ramoshebi LN, Matsaba TN, Teare J, Renton L, Patton J, Ripamonti U. 2002. Tissue engineering: TGF-beta superfamily members and delivery systems in bone regeneration. Expert Rev Mol Med 4:1-11.
4. Rose FR, Hou Q, Oreffo RO. 2004. Delivery systems for bone growth factors - The new players in skeletal regeneration. J Pharm Pharmacol 56:415-427.
5. Varkey M, Gittens SA, Uludag H. 2004. Growth factor delivery for bone tissue repair: An update. Expert Opin Drug Deliv 1:19-36.
6. Burdick JA, Mason MN, Hinman AD, Thorne K, Anseth KS. 2002. Delivery of osteoinductive growth factors from degradable PEG hydrogels influences osteoblast differentiation and mineralization. J Control Release 83:53-63.
7. Roethy W, Fiehn E, Suehiro K, Gu A, Yi GH, Shimizu J, Wang J, Zhang G, Ranieri J, Akella R, Funk SE, Sage EH, Benedict J, Burkhoff D. 2001. A growth factor mixture that significantly enhances angiogenesis in vivo. J Pharmacol Exp Ther 299:494-500.
8. Cho BC, Kim JY, Lee JH, Chung HY, Park JW, Roh KH, Kim GU, Kwon IC, Jang KH, Lee DS, Park NW, Kim IS. 2004. The bone regenerative effect of chitosan microsphere-encapsulated growth hormone on bony consolidation in mandibular distraction osteogenesis in a dog model. J Craniofac Surg 15:299-311; discussion 312-293.
9. Cho BC, Moon JH, Chung HY, Park JW, Kweon IC, Kim IS. 2003. The bone regenerative effect of growth hormone on consolidation in mandibular distraction osteogenesis of a dog model. J Craniofac Surg 14:417-425.
10. Mason JC, Lidington EA, Ahmad SR, Haskard DO. 2002. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol 282:C578-C587.
11. Arese M, Chen Y, Florkiewicz RZ, Gualandris A, Shen B, Rifkin DB. 1999. Nuclear activities of basic fibroblast growth factor: Potentiation of low-serum growth mediated by natural or chimeric nuclear localization signals. Mol Biol Cell 10:1429-1444.
12. Nagai H, Tsukuda R, Mayahara H. 1995. Effects of basic fibroblast growth factor (bFGF) on bone formation in growing rats. Bone 16:367-373.
13. Power RA, Iwaniec UT, Magee KA, Mitova-Caneva NG, Wronski TJ. 2004. Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos Int 15:716-723.
14. Santana RB, Trackman PC. 2006. Controlled release of fibroblast growth factor 2 stimulates bone healing in an animal model of diabetes mellitus. Int J Oral Maxillofac Implants 21:711-718.
15. Dereka XE, Markopoulou CE, Mamalis A, Pepelassi E, Vrotsos IA. 2006. Time- and dose-dependent mitogenic effect of basic fibroblast growth factor combined with different bone graft materials: An in vitro study. Clin Oral Implants Res 17:554-559.
16. Lode A, Wolf-Brandstetter C, Reinstorf A, Bernhardt A, Konig U, Pompe W, Gelinsky M. 2007. Calcium phosphate bone cements, functionalized with VEGF: Release kinetics and biological activity. J Biomed Mater Res A 81:474-483.
17. Murphy WL, Peters MC, Kohn DH, Mooney DJ. 2000. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials 21:2521-2527.
18. Arm DM, Tencer AF, Bain SD, Celino D. 1996. Effect of controlled release of platelet-derived growth factor from a porous hydroxyapatite implant on bone ingrowth. Biomaterials 17:703-709.
19. Delgado JJ, Evora C, Sanchez E, Baro M, Delgado A. 2006. Validation of a method for non-invasive in vivo measurement of growth factor release from a local delivery system in bone. J Control Release 114:223-229.
20. Mogi M, Kondo A, Kinpara K, Togari A. 2000. Antiapoptotic action of nerve growth factor in mouse osteoblastic cell line. Life Sci 67:1197-1206.
21. Letic-Gavrilovic A, Piattelli A, Abe K. 2003. Nerve growth factor beta(NGF beta) delivery via a collagen/hydroxyapatite (Col/HAp) composite and its effects on new bone ingrowth. J Mater Sci Mater Med 14:95-102.
22. Gombotz WR, Pankey SC, Bouchard LS, Phan DH, MacKenzie AP. 1996. Stability, characterization, formulation, and delivery system development for transforming growth factor-beta 1. Pharm Biotechnol 9:219-245.
23. Gombotz WR, Pankey SC, Bouchard LS, Ranchalis J, Puolakkainen P. 1993. Controlled release of TGF-beta 1 from a biodegradable matrix for bone regeneration. J Biomater Sci Polym Ed 5:49-63.
24. Gombotz WR, Pankey SC, Bouchard LS, Phan DH, Puolakkainen PA. 1994. Stimulation of bone healing by transforming growth factor-beta 1 released from polymeric or ceramic implants. J Appl Biomater 5:141-150.
25. Sun JS, Lin FH, Wang YJ, Huang YC, Chueh SC, Hsu FY. 2003. Collagen-hydroxyapatite/tricalcium phosphate microspheres as a delivery system for recombinant human transforming growth factor-beta 1. Artif Organs 27:605-612.
26. Moursi AM, Winnard PL, Fryer D, Mooney MP. 2003. Delivery of transforming growth factor-beta2-perturbing antibody in a collagen vehicle inhibits cranial suture fusion in calvarial organ culture. Cleft Palate Craniofac J 40:225-232.
27. Premaraj S, Mundy B, Parker-Barnes J, Winnard PL, Moursi AM. 2005. Collagen gel delivery of Tgf-beta3 non-viral plasmid DNA in rat osteoblast and calvarial culture. Orthod Craniofac Res 8:320-322.
28. Premaraj S, Mundy BL, Morgan D, Winnard PL, Mooney MP, Moursi AM. 2006. Sustained delivery of bioactive cytokine using a dense collagen gel vehicle collagen gel delivery of bioactive cytokine. Arch Oral Biol 51:325-333.
29. Chen B, Lin H, Wang J, Zhao Y, Wang B, Zhao W, Sun W, Dai J. 2007. Homogeneous osteogenesis and bone regeneration by demineralized bone matrix loading with collagen-targeting bone morphogenetic protein-2. Biomaterials 28:1027-1035.
30. Li C, Vepari C, Jin HJ, Kim HJ, Kaplan DL. 2006. Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials 27:3115-3124.
31. Karageorgiou V, Meinel L, Hofmann S, Malhotra A, Volloch V, Kaplan D. 2004. Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells. J Biomed Mater Res A 71:528-537.
32. Schmoekel HG, Weber FE, Schense JC, Gratz KW, Schawalder P, Hubbell JA. 2005. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng 89:253-262.
33. Schmoekel H, Schense JC, Weber FE, Gratz KW, Gnagi D, Muller R, Hubbell JA. 2004. Bone healing in the rat and dog with nonglycosylated BMP-2 demonstrating low solubility in fibrin matrices. J Orthop Res 22:376-381.
34. Lee TC, Ho JT, Hung KS, Chen WF, Chung YH, Yang YL. 2006. Bone morphogenetic protein gene therapy using a fibrin scaffold for a rabbit spinal-fusion experiment. Neurosurgery 58:373-380; discussion 373-380.
35. Chang PC, Liu BY, Liu CM, Chou HH, Ho MH, Liu HC, Wang DM, Hou LT. 2007. Bone tissue engineering with novel rhBMP2-PLLA composite scaffolds. J Biomed Mater Res A 81:771-780.
36. Hou LT, Liu CM, Liu BY, Chang PC, Chen MH, Ho MH, Jehng SM, Liu HC. 2007. Tissue engineering bone formation in novel recombinant human bone morphogenic protein 2-atelocollagen composite scaffolds. J Periodontol 78:335-343.
37. Liu HW, Chen CH, Tsai CL, Lin IH, Hsiue GH. 2007. Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis. Tissue Eng 13:1113-1124.
38. Jeon O, Song SJ, Kang SW, Putnam AJ, Kim BS. 2007. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials 28:2763-2771.
39. Kato M, Toyoda H, Namikawa T, Hoshino M, Terai H, Miyamoto S, Takaoka K. 2006. Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2). Biomaterials 27:2035-2041.
40. Suzuki A, Terai H, Toyoda H, Namikawa T, Yokota Y, Tsunoda T, Takaoka K. 2006. A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: A potential treatment for infected bone defects. J Orthop Res 24:327-332.
41. Yang XB, Whitaker MJ, Sebald W, Clarke N, Howdle SM, Shakesheff KM, Oreffo RO. 2004. Human osteoprogenitor bone formation using encapsulated bone morphogenetic protein 2 in porous polymer scaffolds. Tissue Eng 10:1037-1045.
42. Nie H, Wang CH. 2007. Fabrication and characterization of PLGA/HAp composite scaffolds for delivery of BMP-2 plasmid DNA. J Control Release 120:111-121.
43. Kaito T, Myoui A, Takaoka K, Saito N, Nishikawa M, Tamai N, Ohgushi H, Yoshikawa H. 2005. Potentiation of the activity of bone morphogenetic protein-2 in bone regeneration by a PLA-PEG/hydroxyapatite composite. Biomaterials 26:73-79.
44. Namikawa T, Terai H, Suzuki E, Hoshino M, Toyoda H, Nakamura H, Miyamoto S, Takahashi N, Ninomiya T, Takaoka K. 2005. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model. Spine 30:1717-1722.
45. Ruhe PQ, Boerman OC, Russel FG, Spauwen PH, Mikos AG, Jansen JA. 2005. Controlled release of rhBMP-2 loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement composites in vivo. J Control Release 106:162-171.
46. Ruhe PQ, Hedberg EL, Padron NT, Spauwen PH, Jansen JA, Mikos AG. 2003. rhBMP-2 release from injectable poly(DL-lactic-co-glycolic acid)/calcium- phosphate cement composites. J Bone Joint Surg Am 85-A:75-81.
47. Lee YM, Nam SH, Seol YJ, Kim TI, Lee SJ, Ku Y, Rhyu IC, Chung CP, Han SB, Choi SM. 2003. Enhanced bone augmentation by controlled release of recombinant human bone morphogenetic protein-2 from bioabsorbable membranes. J Periodontol 74:865-872.
48. Kroese-Deutman HC, Ruhe PQ, Spauwen PH, Jansen JA. 2005. Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits. Biomaterials 26:1131-1138.
49. Schreiber RE, Blease K, Ambrosio A, Amburn E, Sosnowski B, Sampath TK. 2005. Bone induction by AdBMP-2/collagen implants. J Bone Joint Surg Am 87:1059-1068.
50. Barboza EP, Caula AL, Caula Fde O, de Souza RO, Geolas Neto L, Sorensen RG, Li XJ, Wikesjo UM. 2004. Effect of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge with space-providing biomaterials on the augmentation of chronic alveolar ridge defects. J Periodontol 75:702-708.
51. Arnander C, Westermark A, Veltheim R, Docherty-Skogh AC, Hilborn J, Engstrand T. 2006. Three-dimensional technology and bone morphogenetic protein in frontal bone reconstruction. J Craniofac Surg 17:275-279.
52. Akamaru T, Suh D, Boden SD, Kim HS, Minamide A, Louis-Ugbo J. 2003. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine 28:429-434.
53. Kamakura S, Nakajo S, Suzuki O, Sasano Y. 2004. New scaffold for recombinant human bone morphogenetic protein-2. J Biomed Mater Res A 71:299-307.
54. Peel SA, Hu ZM, Clokie CM. 2003. In search of the ideal bone morphogenetic protein delivery system: In vitro studies on demineralized bone matrix, purified, and recombinant bone morphogenetic protein. J Craniofac Surg 14:284-291.
55. Han DK, Kim CS, Jung UW, Chai JK, Choi SH, Kim CK, Cho KS. 2005. Effect of a fibrin-fibronectin sealing system as a carrier for recombinant human bone morphogenetic protein-4 on bone formation in rat calvarial defects. J Periodontol 76:2216-2222.
56. Andreadis GA, Toumba KJ, Curzon ME. 2006. Slow-release fluoride glass devices: In vivo fluoride release and retention of the devices in children. Eur Arch Paediatr Dent 7:258-261.
57. Toumba KJ, Curzon ME. 2005. A clinical trial of a slow-releasing fluoride device in children. Caries Res 39:195-200.
58. Toumba KJ. 2001. Slow-release devices for fluoride delivery to high-risk individuals. Caries Res 35:10-13.
59. Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. 1989. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: Augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 68:150-159.
60. Anderson PA, Copenhaver JC, Tencer AF, Clark JM. 1991. Response of cortical bone to local controlled release of sodium fluoride: The effect of implant insertion site. J Orthop Res 9:890-901.
61. Guise JM, McCormack A, Anderson PA, Tencer AF. 1992. Effect of controlled local release of sodium fluoride on trabecular bone. J Orthop Res 10:588-595.
62. McCormack AP, Anderson PA, Tencer AF. 1993. Effect of controlled local release of sodium fluoride on bone formation: Filling a defect in the proximal femoral cortex. J Orthop Res 11:548-555.
63. Hartley MP, Sanderson S. 2003. Use of antibiotic impregnated polymethylmethacrylate beads for the treatment of chronic mandibular osteomyelitis in a Bennett's wallaby (Macropus rufogriseus rufogriseus). Aust Vet J 81:742-744.
64. Witso E, Persen L, Benum P, Bergh K. 2005. Cortical allograft as a vehicle for antibiotic delivery. Acta Orthop 76:481-486.
65. Ueng SW, Lee MS, Lin SS, Chan EC, Liu SJ. 2007. Development of a biodegradable alginate carrier system for antibiotics and bone cells. J Orthop Res 25:62-72.
66. Bibbo C, Patel DV. 2006. The effect of demineralized bone matrix-calcium sulfate with vancomycin on calcaneal fracture healing and infection rates: A prospective study. Foot Ankle Int 27:487-493.
67. Benghuzzi H, Tucci M, Russell G, Ragab A, Graves M, Conflitti J. 2006. Targeted sustained delivery of tobramycin at the site of a femoral osteotomy. Biomed Sci Instrum 42:530-535.
68. Galjour C, Dzugan S, Graves M, Benghuzzi H, Russell G, Tucci M, Tsao A. 2005. Stimulation of fracture healing by continuous delivery of demineralized bone matrix proteins and tobramycin. Biomed Sci Instrum 41:122-127.
69. Tiainen J, Soini Y, Suokas E, Veiranto M, Tormala P, Waris T, Ashammakhi N. 2006. Tissue reactions to bioabsorbable ciprofloxacin-releasing polylactide-polyglycolide 80/20 screws in rabbits' cranial bone. J Mater Sci Mater Med 17:1315-1322.
70. Makinen TJ, Veiranto M, Lankinen P, Moritz N, Jalava J, Tormala P, Aro HT. 2005. In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler. J Antimicrob Chemother 56:1063-1068.
71. Lee CG, Fu YC, Wang CH. 2005. Simulation of gentamicin delivery for the local treatment of osteomyelitis. Biotechnol Bioeng 91:622-635.
72. El-Ghannam A, Ahmed K, Omran M. 2005. Nanoporous delivery system to treat osteomyelitis and regenerate bone: Gentamicin release kinetics and bactericidal effect. J Biomed Mater Res B Appl Biomater 73:277-284.
73. Luong-Van E, Grondahl L, Nurcombe V, Cool S. 2007. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials 28:2127-2136.
74. Luong-Van E, Grondahl L, Song S, Nurcombe V, Cool S. 2007. The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells. J Mol Histol 38:459-468.
75. Wang D, Bromme D. 2005. Drug delivery strategies for cathepsin inhibitors in joint diseases. Expert Opin Drug Deliv 2:1015-1028.
76. Peter B, Gauthier O, Laib S, Bujoli B, Guicheux J, Janvier P, van Lenthe GH, Muller R, Zambelli PY, Bouler JM, Pioletti DP. 2006. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res A 76:133-143.
77. Tanzer M, Karabasz D, Krygier JJ, Cohen R, Bobyn JD. 2005. The Otto Aufranc Award: Bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res 441:30-39.
78. Hengst V, Oussoren C, Kissel T, Storm G. 2007. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331:224-227.
79. Kim H, Suh H, Jo SA, Kim HW, Lee JM, Kim EH, Reinwald Y, Park SH, Min BH, Jo I. 2005. In vivo bone formation by human marrow stromal cells in biodegradable scaffolds that release dexamethasone and ascorbate-2-phosphate. Biochem Biophys Res Commun 332:1053-1060.
80. Galeska I, Kim TK, Patil SD, Bhardwaj U, Chatttopadhyay D, Papadimitrakopoulos F, Burgess DJ. 2005. Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels. AAPS J 7:E231-E240.
81. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949.
82. Piskin E, Isoglu A, Bolgen N, Griffiths S, Vargel I, Cavusoglu T, Korkusuz P, Guzel E, Cartmell S. 2007. Simvastatin releasing novel PCL scaffolds in rat cranium defects. Tissue Eng 13:1756-1756.
83. Thylin MR, McConnell JC, Schmid MJ, Reckling RR, Ojha J, Bhattacharyya I, Marx DB, Reinhardt RA. 2002. Effects of simvastatin gels on murine calvarial bone. J Periodontol 73:1141-1148.
84. Benoit DS, Nuttelman CR, Collins SD, Anseth KS. 2006. Synthesis and characterization of a fluvastatin-releasing hydrogel delivery system to modulate hMSC differentiation and function for bone regeneration. Biomaterials 27:6102-6110.
85. Adah F, Benghuzzi H, Tucci M, Russell G, England B. 2007. Cholesterol production inhibitor (statin) increased bone healing in surgically created femoral defect in an animal model. Biomed Sci Instrum 43:95-103.
86. Wood MA, Yang Y, Thomas PB, Haj AJ. 2006. Using dihydropyridine-release strategies to enhance load effects in engineered human bone constructs. Tissue Eng 12:2489-2497.
87. Wood MA, Hughes S, Yang Y, El Haj AJ. 2006. Characterizing the efficacy of calcium channel agonist-release strategies for bone tissue engineering applications. J Control Release 112:96-102.